Clinical Trial Update: Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of obeticholic acid (OCA) and bezafibrate (BZF) for Primary Biliary Cholangitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Bezalip (bezafibrate)
• Ocaliva (obeticholic acid)

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Primary Biliary Cholangitis | Phase 2 | Status: TERMINATED